{"id":8116,"date":"2026-06-12T19:47:11","date_gmt":"2026-06-12T16:47:11","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8116"},"modified":"2026-06-12T20:04:35","modified_gmt":"2026-06-12T17:04:35","slug":"if-elevidys-works-why-is-sarepta-stock-falling","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/if-elevidys-works-why-is-sarepta-stock-falling\/","title":{"rendered":"Elevidys Duchenne Kas Distrofisi \u0130\u00e7in \u0130\u015fe Yar\u0131yorsa, Sarepta&#039;n\u0131n Hisse Senedi Neden D\u00fc\u015f\u00fcyor? Ailelerin Gen Terapisi Se\u00e7meden \u00d6nce Bilmesi Gerekenler"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (DMD) tedavileri aras\u0131nda, Sarepta Therapeutics taraf\u0131ndan geli\u015ftirilen gen terapisi Elevidys (delandistrogene moxeparvovec) kadar heyecan, tart\u0131\u015fma ve polemik yaratan \u00e7ok az tedavi y\u00f6ntemi vard\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok aile i\u00e7in Elevidys umudu temsil ediyor. Bu, Duchenne kas distrofisinin alt\u0131nda yatan genetik nedeni hedef alan ve kas h\u00fccrelerine mikro-distrofin geni ileten ilk onayl\u0131 gen terapisidir. Tedavi, 2023 y\u0131l\u0131nda ABD G\u0131da ve \u0130la\u00e7 \u0130daresi&#039;nden (FDA) h\u0131zland\u0131r\u0131lm\u0131\u015f onay ald\u0131 ve daha sonra 2024 y\u0131l\u0131nda geni\u015fletilmi\u015f onay ald\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak ayn\u0131 zamanda Sarepta&#039;n\u0131n hisse senedi fiyat\u0131nda dramatik d\u00fc\u015f\u00fc\u015fler ya\u015fand\u0131, d\u00fczenleyici tart\u0131\u015fmalar ortaya \u00e7\u0131kt\u0131, g\u00fcvenlik endi\u015feleri artt\u0131 ve bir\u00e7ok bilim insan\u0131 klinik faydan\u0131n ger\u00e7ek boyutunu tart\u0131\u015fmaya devam ediyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu durum zorlu ama \u00f6nemli sorular\u0131 g\u00fcndeme getiriyor:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>E\u011fer Elevidys i\u015fe yar\u0131yorsa, Sarepta&#039;n\u0131n hisse senedi neden \u00e7\u00f6kt\u00fc?<\/li>\n\n\n\n<li>Yat\u0131r\u0131mc\u0131lar tedavinin etkisiz oldu\u011funa m\u0131 inan\u0131yor?<\/li>\n\n\n\n<li>Klinik ara\u015ft\u0131rmalar neden baz\u0131 \u00f6nemli hedeflere ula\u015famad\u0131?<\/li>\n\n\n\n<li>Elevidys neden FDA taraf\u0131ndan onaylanm\u0131\u015fken Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) taraf\u0131ndan onaylanmad\u0131?<\/li>\n\n\n\n<li>Aileler tedaviyi al\u0131p almamaya karar vermeden \u00f6nce neleri anlamal\u0131d\u0131r?<\/li>\n\n\n\n<li>Elevidys gen terapisinin bug\u00fcn al\u0131nmas\u0131, gelecekteki tedaviler i\u00e7in uygunlu\u011fu etkileyebilir mi?<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu sorular duygusal sosyal medya tart\u0131\u015fmalar\u0131ndan ziyade kan\u0131tlara dayal\u0131 cevaplar\u0131 hak ediyor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#understanding-what-elevidys-actually-does\">Elevidys'in Ger\u00e7ekte Ne \u0130\u015fe Yarad\u0131\u011f\u0131n\u0131 Anlamak<\/a><ul><\/ul><\/li><li><a href=\"#if-elevidys-works-why-has-sareptas-stock-fallen-so-dramatically\">E\u011fer Elevidys i\u015fe yar\u0131yorsa, Sarepta'n\u0131n hisseleri neden bu kadar d\u00fc\u015ft\u00fc?<\/a><ul><\/ul><\/li><li><a href=\"#why-viral-videos-should-not-be-used-as-scientific-evidence\">Viral Videolar Neden Bilimsel Kan\u0131t Olarak Kullan\u0131lmamal\u0131d\u0131r?<\/a><ul><\/ul><\/li><li><a href=\"#are-nsaa-scores-enough-to-measure-success\">NSAA Puanlar\u0131 Ba\u015far\u0131y\u0131 \u00d6l\u00e7mek \u0130\u00e7in Yeterli mi?<\/a><ul><\/ul><\/li><li><a href=\"#how-many-extra-years-could-elevidys-add\">O\u011flum Elevidys ald\u0131ktan sonra ka\u00e7 y\u0131l daha ya\u015fayacak?<\/a><ul><\/ul><\/li><li><a href=\"#is-elevidys-worth-3-2-million\">Elevidys 3,2 milyon ABD dolar\u0131 eder mi?<\/a><ul><\/ul><\/li><li><a href=\"#why-is-elevidys-approved-by-the-fda-but-not-by-the-ema\">Elevidys neden FDA taraf\u0131ndan onaylan\u0131rken EMA taraf\u0131ndan onaylanm\u0131yor?<\/a><ul><\/ul><\/li><li><a href=\"#could-receiving-elevidys-limit-future-treatment-options\">Elevidys Almak Gelecekteki Tedavi Se\u00e7eneklerini S\u0131n\u0131rlayabilir mi?<\/a><ul><\/ul><\/li><li><a href=\"#what-new-duchenne-therapies-are-coming\">Yeni Duchenne Tedavileri Nelerdir?<\/a><ul><\/ul><\/li><li><a href=\"#why-families-continue-campaigning-for-elevidys\">Aileler Elevidys i\u00e7in Kampanyaya Neden Devam Ediyor?<\/a><\/li><li><a href=\"#questions-every-family-should-ask-before-choosing-elevidys\">Elevidys'i Se\u00e7meden \u00d6nce Her Ailenin Sormas\u0131 Gereken Sorular<\/a><\/li><li><a href=\"#conclusion\">Sonu\u00e7<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"understanding-what-elevidys-actually-does\" class=\"wp-block-heading\">Elevidys'in Ger\u00e7ekte Ne \u0130\u015fe Yarad\u0131\u011f\u0131n\u0131 Anlamak<\/h2>\n\n\n\n<h3 id=\"elevidys-is-not-a-full-dystrophin-replacement\" class=\"wp-block-heading\">Elevidys Tam Bir Distrofin Yerine Ge\u00e7mez<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi, DMD genindeki mutasyonlar nedeniyle kas liflerini hasardan koruyan kritik bir protein olan distrofinin i\u015flevsel olarak \u00fcretilememesi sonucu ortaya \u00e7\u0131kar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys, distrofin geninin tamam\u0131n\u0131 geri kazand\u0131rmaz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunun yerine, adeno-ili\u015fkili vir\u00fcs (AAV) vekt\u00f6r\u00fc kullan\u0131larak mikro-distrofin ad\u0131 verilen k\u0131salt\u0131lm\u0131\u015f bir versiyonu verilir. Bu terapi, tam distrofin geninin mevcut AAV da\u011f\u0131t\u0131m sistemlerine s\u0131\u011famayacak kadar b\u00fcy\u00fck olmas\u0131 nedeniyle tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu ayr\u0131m \u00f6nemlidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu terapi, kas h\u00fccrelerini k\u0131smen koruyabilecek daha k\u00fc\u00e7\u00fck bir distrofin benzeri protein \u00fcretmeyi ama\u00e7lamaktad\u0131r, ancak sa\u011fl\u0131kl\u0131 bireylerde bulunan do\u011fal distrofin proteininin tamam\u0131n\u0131 yeniden olu\u015fturmaz. \u00c7al\u0131\u015fmalar, tedaviden sonra mikro-distrofin ekspresyonunun s\u00fcrd\u00fcr\u00fcld\u00fc\u011f\u00fcn\u00fc g\u00f6stermi\u015ftir ve bu da FDA onay\u0131n\u0131n temel dayanaklar\u0131ndan biri olmu\u015ftur.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"if-elevidys-works-why-has-sareptas-stock-fallen-so-dramatically\" class=\"wp-block-heading\">E\u011fer Elevidys i\u015fe yar\u0131yorsa, Sarepta'n\u0131n hisseleri neden bu kadar d\u00fc\u015ft\u00fc?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok aile, hisse senedi fiyat\u0131ndaki d\u00fc\u015f\u00fc\u015f\u00fcn otomatik olarak tedavinin i\u015fe yaramad\u0131\u011f\u0131 anlam\u0131na geldi\u011fini varsayar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Biyoteknolojide ger\u00e7eklik \u00e7ok daha karma\u015f\u0131k.<\/p>\n\n\n\n<h3 id=\"investor-concerns-extend-beyond-clinical-results\" class=\"wp-block-heading\">Yat\u0131r\u0131mc\u0131lar\u0131n Endi\u015feleri Klinik Sonu\u00e7lar\u0131n \u00d6tesine Uzan\u0131yor<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yat\u0131r\u0131mc\u0131lar \u015funlar\u0131 de\u011ferlendirir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>G\u00fcvenlik riskleri<\/li>\n\n\n\n<li>D\u00fczenleyici belirsizlik<\/li>\n\n\n\n<li>Ticari kullan\u0131m<\/li>\n\n\n\n<li>Sigorta geri \u00f6demesi<\/li>\n\n\n\n<li>Gelecekteki rekabet<\/li>\n\n\n\n<li>Uzun vadeli etkinlik<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bir tedavinin herhangi bir fayda sa\u011flay\u0131p sa\u011flamad\u0131\u011f\u0131n\u0131 sormaktan ziyade.<\/p>\n\n\n\n<h3 id=\"safety-concerns-have-had-major-impact\" class=\"wp-block-heading\">G\u00fcvenlik endi\u015feleri b\u00fcy\u00fck etki yaratt\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">2025 y\u0131l\u0131 boyunca, gen terapisi programlar\u0131yla ili\u015fkili akut karaci\u011fer yetmezli\u011fi vakalar\u0131 ve hasta \u00f6l\u00fcmleri, d\u00fczenleyici kurumlar ve yat\u0131r\u0131mc\u0131lar taraf\u0131ndan daha yo\u011fun bir incelemeye yol a\u00e7t\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA daha sonra Elevidys re\u00e7eteleme bilgilerini g\u00fcncelledi ve akut ciddi karaci\u011fer hasar\u0131 ve akut karaci\u011fer yetmezli\u011fi ile ilgili daha g\u00fc\u00e7l\u00fc g\u00fcvenlik uyar\u0131lar\u0131 ekledi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu olaylar a\u011f\u0131rl\u0131kl\u0131 olarak hareket edemeyen hastalar aras\u0131nda meydana gelmi\u015f olsa da, yat\u0131r\u0131mc\u0131 g\u00fcvenini \u00f6nemli \u00f6l\u00e7\u00fcde etkiledi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yat\u0131r\u0131mc\u0131lar yaln\u0131zca bir tedavinin i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131 konusunda de\u011fil, ayn\u0131 zamanda d\u00fczenleyicilerin gelecekte kullan\u0131m\u0131n\u0131 k\u0131s\u0131tlay\u0131p k\u0131s\u0131tlamayaca\u011f\u0131 konusunda da endi\u015feleniyorlar.<\/p>\n\n\n\n<h3 id=\"clinical-trial-results-have-been-interpreted-differently\" class=\"wp-block-heading\">Klinik Ara\u015ft\u0131rma Sonu\u00e7lar\u0131 Farkl\u0131 \u015eekillerde Yorumland\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">En b\u00fcy\u00fck tart\u0131\u015fma kaynaklar\u0131ndan biri EMBARK Faz 3 \u00e7al\u0131\u015fmas\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Orijinal plasebo kontroll\u00fc EMBARK \u00e7al\u0131\u015fmas\u0131, plaseboya k\u0131yasla North Star Ambulatory Assessment (NSAA) puanlar\u0131nda iyile\u015fme sa\u011flamay\u0131 i\u00e7eren birincil hedefine ula\u015famad\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak, \u00e7ok say\u0131da ikincil sonu\u00e7 noktas\u0131 Elevidys lehine sonu\u00e7 verdi ve daha sonraki analizler hastal\u0131\u011f\u0131n ilerlemesinin yava\u015flad\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Destek\u00e7iler, Duchenne hastal\u0131\u011f\u0131n\u0131n ilerlemesinin yava\u015f oldu\u011funu ve k\u0131sa zaman dilimlerinde \u00f6l\u00e7\u00fclmesinin zor oldu\u011funu savunuyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ele\u015ftirmenler, birincil hedef noktas\u0131na ula\u015f\u0131lamamas\u0131n\u0131n etkinli\u011fe ili\u015fkin soru i\u015faretleri do\u011furmas\u0131 gerekti\u011fini savunuyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sonu\u00e7, bilimsel fikir birli\u011fi yerine bilimsel g\u00f6r\u00fc\u015f ayr\u0131l\u0131\u011f\u0131d\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-viral-videos-should-not-be-used-as-scientific-evidence\" class=\"wp-block-heading\">Viral Videolar Neden Bilimsel Kan\u0131t Olarak Kullan\u0131lmamal\u0131d\u0131r?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Aileler s\u0131kl\u0131kla, \u00e7ocuklar\u0131n tedavi \u00f6ncesi ve sonras\u0131 hallerini g\u00f6steren \u00e7arp\u0131c\u0131 sosyal medya videolar\u0131yla kar\u015f\u0131la\u015f\u0131yorlar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu videolar duygusal olarak \u00e7ok etkileyici olabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak bunlar bilimsel kan\u0131t de\u011fildir.<\/p>\n\n\n\n<h3 id=\"the-problem-with-anecdotal-evidence\" class=\"wp-block-heading\">Anekdot Niteli\u011findeki Kan\u0131tlar\u0131n Sorunu<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bir \u00e7ocukta a\u015fa\u011f\u0131dakiler g\u00f6r\u00fclebilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>daha g\u00fc\u00e7l\u00fc<\/li>\n\n\n\n<li>daha h\u0131zl\u0131<\/li>\n\n\n\n<li>daha enerjik<\/li>\n\n\n\n<li>daha istikrarl\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Tedaviyle ilgisi olmayan bir\u00e7ok nedenden dolay\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fakt\u00f6rler \u015funlard\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>b\u00fcy\u00fcme<\/li>\n\n\n\n<li>fizyoterapi<\/li>\n\n\n\n<li>kortikosteroid kullan\u0131m\u0131<\/li>\n\n\n\n<li>motivasyon<\/li>\n\n\n\n<li>do\u011fal de\u011fi\u015fkenlik<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">K\u0131sa bir video klip, bir tedavinin hastal\u0131\u011f\u0131n ilerleyi\u015fini de\u011fi\u015ftirip de\u011fi\u015ftirmedi\u011fini belirleyemez.<\/p>\n\n\n\n<h3 id=\"objective-biomarkers-matter-more\" class=\"wp-block-heading\">Objektif Biyobelirte\u00e7ler Daha \u00d6nemlidir<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aileler a\u015fa\u011f\u0131daki konularda \u015feffaf raporlama talep etmelidir:<\/p>\n\n\n\n<h4 id=\"ck-creatine-kinase\" class=\"wp-block-heading\">CK (Kreatin Kinaz)<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">CK, Duchenne kas distrofisinde en \u00f6nemli biyobelirte\u00e7lerden biridir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kas h\u00fccreleri hasar g\u00f6rd\u00fc\u011f\u00fcnde, CK kan dola\u015f\u0131m\u0131na s\u0131zar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tedaviden sonra CK seviyelerinin d\u00fc\u015fmesi, kas hasar\u0131n\u0131n azald\u0131\u011f\u0131n\u0131 g\u00f6sterebilir.<\/p>\n\n\n\n<h4 id=\"ast-and-alt\" class=\"wp-block-heading\">AST ve ALT<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">AST ve ALT genellikle karaci\u011fer enzimleri olarak kabul edilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak Duchenne kas distrofisinde, y\u00fcksek AST ve ALT seviyeleri hasar g\u00f6rm\u00fc\u015f kas dokusundan da kaynaklanabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu g\u00f6stergelerin zaman i\u00e7inde izlenmesi, hem kas sa\u011fl\u0131\u011f\u0131 hem de tedavi g\u00fcvenli\u011fi konusunda \u00f6nemli bilgiler sa\u011flayabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">E\u011fer Elevidys ger\u00e7ekten kas liflerini koruyorsa, bir\u00e7ok uzman CK e\u011filimlerinin fonksiyonel sonu\u00e7lar kadar dikkat \u00e7ekmeyi hak etti\u011fini savunuyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/ck-levels-after-duchenne-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne Gen Terapisinde CK, AST ve ALT Verilerinin Videolardan Daha \u00d6nemli Olmas\u0131n\u0131n Sebebi<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"are-nsaa-scores-enough-to-measure-success\" class=\"wp-block-heading\">NSAA Puanlar\u0131 Ba\u015far\u0131y\u0131 \u00d6l\u00e7mek \u0130\u00e7in Yeterli mi?<\/h2>\n\n\n\n<h3 id=\"what-is-nsaa\" class=\"wp-block-heading\">NSAA Nedir?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">North Star Ambulatuvar De\u011ferlendirme, Duchenne klinik \u00e7al\u0131\u015fmalar\u0131nda yayg\u0131n olarak kullan\u0131lmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A\u015fa\u011f\u0131daki gibi faaliyetleri de\u011ferlendirir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>aya\u011fa kalkma<\/li>\n\n\n\n<li>y\u00fcr\u00fcme<\/li>\n\n\n\n<li>t\u0131rmanma<\/li>\n\n\n\n<li>s\u0131\u00e7rama<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Daha y\u00fcksek puanlar daha iyi motor fonksiyonu g\u00f6sterir. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/north-star-ambulatory-assessment-nsaa-in-duchenne-dmd\/\" target=\"_blank\" data-type=\"post\" data-id=\"4959\" rel=\"noreferrer noopener\">NSAA nedir?<\/a><\/p>\n\n\n\n<h3 id=\"the-limitations-of-nsaa\" class=\"wp-block-heading\">NSAA&#039;n\u0131n S\u0131n\u0131rlamalar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">NSAA \u015funlardan etkilenebilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ya\u015f<\/li>\n\n\n\n<li>motivasyon<\/li>\n\n\n\n<li>t\u00fckenmi\u015flik<\/li>\n\n\n\n<li>de\u011ferlendirici farkl\u0131l\u0131klar\u0131<\/li>\n\n\n\n<li>\u00f6\u011frenme etkileri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bir \u00e7ocuk, anlaml\u0131 bir biyolojik iyile\u015fme ya\u015famadan ge\u00e7ici olarak iyile\u015fme g\u00f6sterebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu nedenle bir\u00e7ok ara\u015ft\u0131rmac\u0131, NSAA&#039;n\u0131n biyolojik belirte\u00e7lerle birlikte yorumlanmas\u0131 gerekti\u011fine inanmaktad\u0131r.<\/p>\n\n\n\n<h3 id=\"why-dystrophin-production-matters\" class=\"wp-block-heading\">Distrofin \u00dcretiminin \u00d6nemi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6zetle, Duchenne hastal\u0131\u011f\u0131na distrofin eksikli\u011fi neden olur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Distrofinin yerine ge\u00e7mesi ama\u00e7lanan bir tedavi ideal olarak \u015fu \u00f6zellikleri g\u00f6stermelidir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>sa\u011flam protein \u00fcretimi<\/li>\n\n\n\n<li>s\u00fcrekli ifade<\/li>\n\n\n\n<li>kas koruma<\/li>\n\n\n\n<li>uzun vadeli fonksiyonel fayda<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Mikro-distrofin \u00fcretimi, FDA de\u011ferlendiricilerinin Elevidys'i biyolojik olarak aktif olarak de\u011ferlendirmesinin ba\u015fl\u0131ca nedenlerinden biriydi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak bilim insanlar\u0131, anlaml\u0131 klinik fayda sa\u011flamak i\u00e7in ne kadar mikro-distrofinin gerekli oldu\u011fu konusunda tart\u0131\u015fmaya devam ediyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/biomarkers-in-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">NSAA tek ba\u015f\u0131na yeterli de\u011fil<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"how-many-extra-years-could-elevidys-add\" class=\"wp-block-heading\">O\u011flum Elevidys ald\u0131ktan sonra ka\u00e7 y\u0131l daha ya\u015fayacak?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu belki de ailelerin sordu\u011fu en \u00f6nemli sorudur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Maalesef kimse bilmiyor.<\/p>\n\n\n\n<h3 id=\"no-survival-benefit-has-yet-been-proven\" class=\"wp-block-heading\">Hen\u00fcz Hayatta Kalma A\u00e7\u0131s\u0131ndan Bir Faydas\u0131 Kan\u0131tlanmad\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys&#039;nin ya\u015fam beklentisini uzat\u0131p uzatmad\u0131\u011f\u0131n\u0131 g\u00f6stermek i\u00e7in yeterince uzun s\u00fcredir piyasada bulunmamaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>2 y\u0131l<\/li>\n\n\n\n<li>5 y\u0131l<\/li>\n\n\n\n<li>10 y\u0131l<\/li>\n\n\n\n<li>20 y\u0131l<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Uzun vadeli hayatta kalma \u00e7al\u0131\u015fmalar\u0131 hen\u00fcz mevcut de\u011fil.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ya\u015fam s\u00fcresinin kesin olarak uzat\u0131laca\u011f\u0131na dair her t\u00fcrl\u00fc iddia \u015fu anda spek\u00fclasyondan ibarettir.<\/p>\n\n\n\n<h3 id=\"what-clinical-trials-suggest\" class=\"wp-block-heading\">Klinik Ara\u015ft\u0131rmalar Ne \u00d6ne S\u00fcr\u00fcyor?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Son yap\u0131lan takip analizleri, Elevidys varyant\u0131n\u0131n do\u011fal seyir g\u00f6steren gruplara k\u0131yasla hastal\u0131k ilerlemesini yava\u015flatabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lerlemenin yava\u015flamas\u0131n\u0131n daha uzun s\u00fcreler boyunca do\u011frulanmas\u0131 durumunda, bu teorik olarak \u015funlar\u0131 geciktirebilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>y\u00fcr\u00fcme yetene\u011finin kayb\u0131<\/li>\n\n\n\n<li>solunumda azalma<\/li>\n\n\n\n<li>kalp komplikasyonlar\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak, ya\u015fam s\u00fcresinin uzad\u0131\u011f\u0131n\u0131 kan\u0131tlamak i\u00e7in daha uzun y\u0131llar g\u00f6zlem yap\u0131lmas\u0131 gerekmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aileler, mevcut kan\u0131tlar\u0131n biyolojik aktiviteyi ve potansiyel fonksiyonel fayday\u0131 g\u00f6sterdi\u011fini, ancak ya\u015fam s\u00fcresini uzatmay\u0131 kan\u0131tlamad\u0131\u011f\u0131n\u0131 anlamal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/elevidys-gene-therapy-efficacy-in-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Elevidys Gen Terapisi, Duchenne Musk\u00fcler Distrofisi (DMD) Olan \u00c7ocuklar\u0131n Durumunu Ne Kadar \u0130yile\u015ftiriyor?<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"is-elevidys-worth-3-2-million\" class=\"wp-block-heading\">Elevidys 3,2 milyon ABD dolar\u0131 eder mi?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys'in tedavi ba\u015f\u0131na bildirilen maliyeti yakla\u015f\u0131k 3,2 milyon ABD dolar\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu da onu d\u00fcnyan\u0131n en pahal\u0131 ila\u00e7lar\u0131ndan biri yap\u0131yor.<\/p>\n\n\n\n<h3 id=\"the-economic-question\" class=\"wp-block-heading\">Ekonomik Soru<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">De\u011fer \u015funlara ba\u011fl\u0131d\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>faydan\u0131n b\u00fcy\u00fckl\u00fc\u011f\u00fc<\/li>\n\n\n\n<li>faydan\u0131n s\u00fcresi<\/li>\n\n\n\n<li>g\u00fcvenlik profili<\/li>\n\n\n\n<li>gelecekteki tedavi se\u00e7enekleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bir tedavi sa\u011fl\u0131kl\u0131 ya\u015fam s\u00fcresine on y\u0131llar ekliyorsa, bir\u00e7ok ki\u015fi bunun de\u011ferli oldu\u011funu savunacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Faydan\u0131n m\u00fctevaz\u0131 oldu\u011fu ortaya \u00e7\u0131karsa, de\u011fer \u00f6nerisi daha tart\u0131\u015fmal\u0131 hale gelir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eu anda, uzun vadeli sonu\u00e7lar bilinmedi\u011finden, ger\u00e7ek uzun vadeli de\u011fer belirsizli\u011fini koruyor.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-is-elevidys-approved-by-the-fda-but-not-by-the-ema\" class=\"wp-block-heading\">Elevidys neden FDA taraf\u0131ndan onaylan\u0131rken EMA taraf\u0131ndan onaylanm\u0131yor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok aile, bir d\u00fczenleyici kurumdan onay alman\u0131n, ba\u015fka yerlerden de onay al\u0131naca\u011f\u0131 anlam\u0131na geldi\u011fini varsayar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu her zaman do\u011fru de\u011fildir.<\/p>\n\n\n\n<h3 id=\"different-regulatory-standards\" class=\"wp-block-heading\">Farkl\u0131 D\u00fczenleyici Standartlar<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA ve EMA a\u015fa\u011f\u0131daki hususlar\u0131 de\u011ferlendirebilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>risk tolerans\u0131<\/li>\n\n\n\n<li>klinik sonu\u00e7lar<\/li>\n\n\n\n<li>istatistiksel kan\u0131t<\/li>\n\n\n\n<li>kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">farkl\u0131 \u015fekilde.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA, ge\u00e7mi\u015fte tedavi se\u00e7eneklerinin yetersiz oldu\u011fu ciddi hastal\u0131klar i\u00e7in h\u0131zland\u0131r\u0131lm\u0131\u015f onay yollar\u0131n\u0131 kullanmaya istekli oldu\u011funu g\u00f6stermi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Avrupa d\u00fczenleyici kurumlar\u0131 bazen onay vermeden \u00f6nce daha g\u00fc\u00e7l\u00fc teyit edici kan\u0131tlar talep eder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, bir kurumun hakl\u0131, di\u011ferinin haks\u0131z oldu\u011fu anlam\u0131na gelmez.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, mevcut kan\u0131tlar\u0131n farkl\u0131 yorumlar\u0131n\u0131 yans\u0131tmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/why-elevidys-was-not-approved-by-the-european-medicines-agency-ema\/\" target=\"_blank\" rel=\"noreferrer noopener\">Elevidys Neden Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) Taraf\u0131ndan Onaylanmad\u0131?<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"could-receiving-elevidys-limit-future-treatment-options\" class=\"wp-block-heading\">Elevidys Almak Gelecekteki Tedavi Se\u00e7eneklerini S\u0131n\u0131rlayabilir mi?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu soru, hak etti\u011finden \u00e7ok daha az tart\u0131\u015f\u0131l\u0131yor.<\/p>\n\n\n\n<h3 id=\"the-aav-antibody-problem\" class=\"wp-block-heading\">AAV Antikor Sorunu<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys, AAV vekt\u00f6r\u00fc kullan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tedaviden sonra ba\u011f\u0131\u015f\u0131kl\u0131k sistemi bu vekt\u00f6re kar\u015f\u0131 antikorlar geli\u015ftirebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu durum, gelecekteki yeniden dozlama i\u015flemleri i\u00e7in zorluklar yaratmaktad\u0131r.<\/p>\n\n\n\n<h3 id=\"potential-impact-on-future-gene-therapies\" class=\"wp-block-heading\">Gelecekteki Gen Terapileri \u00dczerindeki Potansiyel Etki<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yeni nesil gen terapilerinin \u00e7o\u011fu da AAV teknolojilerine dayanmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aileler \u015fu sorular\u0131 sormal\u0131:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gelecekteki tedavilerde benzer vekt\u00f6rler kullan\u0131lacak m\u0131?<\/li>\n\n\n\n<li>Yine de elemeleri ge\u00e7ebilecek miyim?<\/li>\n\n\n\n<li>Yeniden dozlama stratejileri geli\u015ftiriliyor mu?<\/li>\n\n\n\n<li>Hangi alternatifler ortaya \u00e7\u0131kabilir?<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu sorular ve cevaplar\u0131 tedaviden sonra de\u011fil, \u00f6nce yap\u0131lmal\u0131d\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"what-new-duchenne-therapies-are-coming\" class=\"wp-block-heading\">Yeni Duchenne Tedavileri Nelerdir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne tedavileri h\u0131zla geli\u015fiyor.<\/p>\n\n\n\n<h3 id=\"next-generation-gene-therapies\" class=\"wp-block-heading\">Yeni Nesil Gen Terapileri<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7e\u015fitli \u015firketler, distrofin ekspresyonunu art\u0131rmay\u0131 veya g\u00fcvenli\u011fi iyile\u015ftirmeyi ama\u00e7layan geli\u015ftirilmi\u015f yakla\u015f\u0131mlar \u00fczerinde \u00e7al\u0131\u015f\u0131yor. Daha fazla bilgi i\u00e7in: <a href=\"https:\/\/dmdwarrior.com\/tr\/new-gene-therapies-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne Kas Distrofisi \u0130\u00e7in Potansiyel Yeni Gen Terapileri<\/a><\/p>\n\n\n\n<h3 id=\"cell-therapies\" class=\"wp-block-heading\">H\u00fccre Terapileri<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rmac\u0131lar, hasar g\u00f6rm\u00fc\u015f kas dokusunu yenileyebilecek h\u00fccre bazl\u0131 tedavileri ara\u015ft\u0131r\u0131yor.<\/p>\n\n\n\n<h3 id=\"m-rna-therapies\" class=\"wp-block-heading\">mRNA Terapileri<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yeni ortaya \u00e7\u0131kan mRNA yakla\u015f\u0131mlar\u0131, mikro-distrofin yerine tam uzunlukta distrofin \u00fcretimini m\u00fcmk\u00fcn k\u0131lmay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu strateji, AAV vekt\u00f6rleriyle ili\u015fkili boyut s\u0131n\u0131rlamalar\u0131n\u0131n \u00fcstesinden gelebilece\u011fi i\u00e7in b\u00fcy\u00fck ilgi \u00e7ekmi\u015ftir.<\/p>\n\n\n\n<h3 id=\"gene-editing\" class=\"wp-block-heading\">Gen D\u00fczenleme<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CRISPR tabanl\u0131 yakla\u015f\u0131mlar deneysel a\u015famada kalmaktad\u0131r ancak kal\u0131c\u0131 genetik d\u00fczeltme olas\u0131l\u0131\u011f\u0131 sunmaktad\u0131r.<\/p>\n\n\n\n<h3 id=\"full-length-dystrophin-strategies\" class=\"wp-block-heading\">Tam Uzunlukta Distrofin Stratejileri<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok ara\u015ft\u0131rmac\u0131, tam uzunlukta distrofin restorasyonunu nihai hedef olarak g\u00f6r\u00fcyor \u00e7\u00fcnk\u00fc bu, do\u011fal biyolojiye en \u00e7ok benzeyen durum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gelecekteki tedavilerin bunu g\u00fcvenli bir \u015fekilde ba\u015far\u0131p ba\u015faramayaca\u011f\u0131 hen\u00fcz bilinmiyor.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-families-continue-campaigning-for-elevidys\" class=\"wp-block-heading\">Aileler Elevidys i\u00e7in Kampanyaya Neden Devam Ediyor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ele\u015ftirmenler bazen ailelerin bilgisiz oldu\u011funu varsayarlar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu varsay\u0131m \u00e7o\u011fu zaman haks\u0131zd\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7o\u011fu aile, Duchenne kas distrofisinin amans\u0131z bir \u015fekilde ilerleyici oldu\u011funu bilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her y\u0131l \u00f6nemlidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her ay \u00f6nemlidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ebeveynler s\u0131kl\u0131kla, bir daha asla geri gelmeyebilecek bir f\u0131rsat\u0131 kaybetme korkusuyla tedavi y\u00f6ntemini tercih ederler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Destek\u00e7iler \u015fu g\u00f6r\u00fc\u015f\u00fc savunuyor:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Beklemek riskler i\u00e7erir<\/li>\n\n\n\n<li>Hastal\u0131\u011f\u0131n ilerlemesi devam ediyor<\/li>\n\n\n\n<li>Gelecekteki tedaviler hen\u00fcz belirsiz<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u015e\u00fcpheciler \u015fu iddiada bulunuyor:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kan\u0131tlar hen\u00fcz tamamlanmad\u0131<\/li>\n\n\n\n<li>Uzun vadeli faydas\u0131 bilinmiyor<\/li>\n\n\n\n<li>Gelecekteki tedaviler daha b\u00fcy\u00fck avantajlar sunabilir<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Her iki bak\u0131\u015f a\u00e7\u0131s\u0131 da anla\u015f\u0131labilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"questions-every-family-should-ask-before-choosing-elevidys\" class=\"wp-block-heading\">Elevidys'i Se\u00e7meden \u00d6nce Her Ailenin Sormas\u0131 Gereken Sorular<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Biyolojik fayday\u0131 g\u00f6steren kan\u0131tlar nelerdir?<\/li>\n\n\n\n<li>\u0130\u015flevsel fayday\u0131 g\u00f6steren kan\u0131tlar nelerdir?<\/li>\n\n\n\n<li>Uzun vadeli g\u00fcvenlik verileri nelerdir?<\/li>\n\n\n\n<li>Daha iyi tedavi y\u00f6ntemleri ortaya \u00e7\u0131karsa ne olur?<\/li>\n\n\n\n<li>Gelecekteki uygunluk \u015fartlar\u0131 etkilenebilir mi?<\/li>\n\n\n\n<li>\u00c7ocu\u011fumun mevcut hastal\u0131k belirtileri nelerdir?<\/li>\n\n\n\n<li>Risk-fayda profili benim \u00e7ocu\u011fum i\u00e7in \u00f6zel olarak nas\u0131l uygulan\u0131r?<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Hi\u00e7bir sosyal medya videosu bu sorular\u0131 yan\u0131tlayamaz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunun i\u00e7in ancak kan\u0131tlar\u0131n dikkatli bir \u015fekilde incelenmesi ve deneyimli n\u00f6rom\u00fcsk\u00fcler uzmanlarla g\u00f6r\u00fc\u015f\u00fclmesi gerekir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/frequently-asked-questions-about-elevidys-used-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Elevidys Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"conclusion\" class=\"wp-block-heading\">Sonu\u00e7<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys etraf\u0131ndaki tart\u0131\u015fma, modern t\u0131bb\u0131n en zorlu zorluklar\u0131ndan birini ortaya koyuyor: belirsizlik ortam\u0131nda hayat de\u011fi\u015ftiren kararlar almak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys'in mikro-distrofin \u00fcretti\u011fi ve biyolojik aktivite g\u00f6sterdi\u011fi konusunda \u00e7ok az \u015f\u00fcphe vard\u0131r. Uzun s\u00fcreli takip verileri ayr\u0131ca, hastal\u0131\u011f\u0131n ilerlemesinin en az\u0131ndan baz\u0131 hastalarda yava\u015flat\u0131labilece\u011fini de g\u00f6stermektedir. Bununla birlikte, kal\u0131c\u0131l\u0131k, g\u00fcvenlik, hayatta kalma avantaj\u0131, maliyet etkinli\u011fi ve tedavinin gelecekteki tedavi se\u00e7enekleri \u00fczerindeki etkisiyle ilgili \u00f6nemli sorular hala yan\u0131tlanmay\u0131 beklemektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elevidys gen terapisinin destek\u00e7ileri s\u0131kl\u0131kla FDA onaylanmas\u0131na ve umut vadeden klinik bulgulara i\u015faret ediyor. Ele\u015ftirmenler ise CK, AST, ALT gibi biyobelirte\u00e7lerin, uzun vadeli fonksiyonel sonu\u00e7lar ve hayatta kalma beklentileri konusunda daha fazla \u015feffafl\u0131\u011fa ihtiya\u00e7 oldu\u011funu savunuyor. Bu \u00e7\u00f6z\u00fclmemi\u015f sorular, Duchenne kas distrofisi toplulu\u011fu i\u00e7inde tart\u0131\u015fmalar\u0131 k\u00f6r\u00fcklemeye devam ediyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sarepta&#039;n\u0131n hisse fiyat\u0131ndaki dramatik d\u00fc\u015f\u00fc\u015f (yakla\u015f\u0131k 15 ay i\u00e7inde 122 ABD dolar\u0131ndan 15 ABD dolar\u0131na kadar), bir biyoteknoloji \u015firketi i\u00e7in tipik bir dalgalanma de\u011fildir. Hisse senedi performans\u0131 tek ba\u015f\u0131na bir tedavinin i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131 belirleyemezken, bu kadar b\u00fcy\u00fck bir piyasa de\u011feri kayb\u0131, bir\u00e7ok yat\u0131r\u0131mc\u0131n\u0131n mevcut veriler, g\u00fcvenlik geli\u015fmeleri, d\u00fczenleyici belirsizlik, gelecekteki rekabet ve tedavinin genel risk-fayda profili konusunda giderek daha fazla endi\u015fe duydu\u011funu g\u00f6stermektedir. Bu endi\u015felerin nihayetinde hakl\u0131 olup olmad\u0131\u011f\u0131 hen\u00fcz belli de\u011fil, ancak d\u00fc\u015f\u00fc\u015f a\u00e7\u0131k\u00e7a yat\u0131r\u0131mc\u0131 g\u00fcveninde \u00f6nemli bir kayb\u0131 yans\u0131tmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"conclusion\">Ancak aileler i\u00e7in en \u00f6nemli soru, yat\u0131r\u0131mc\u0131lar\u0131n Elevidys'e g\u00fcvenip g\u00fcvenmedi\u011fi de\u011fil. En \u00f6nemli soru, mevcut kan\u0131tlar\u0131n bug\u00fcn tedaviyi hakl\u0131 \u00e7\u0131karmaya yeterli olup olmad\u0131\u011f\u0131 veya ek veriler ve yeni nesil tedaviler i\u00e7in beklemenin \u00e7ocuklar\u0131 i\u00e7in daha iyi bir se\u00e7im olup olmad\u0131\u011f\u0131d\u0131r. Her aile, \u00e7ocuklar\u0131n\u0131n gelece\u011fini \u015fekillendirebilecek bir karar vermeden \u00f6nce \u015feffaf bilgiye, belirsizlikler hakk\u0131nda d\u00fcr\u00fcst tart\u0131\u015fmalara ve mevcut t\u00fcm kan\u0131tlara eri\u015fime hak kazan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Son bir d\u00fc\u015f\u00fcnce: E\u011fer biri size &quot;CK&#039;n\u0131n \u00f6nemi yok&quot; derse, kan\u0131t olmadan bu iddiay\u0131 kabul etmeyin. Duchenne kas distrofisi, devam eden kas hasar\u0131yla tan\u0131mlanan bir hastal\u0131kt\u0131r ve CK, bu hasar\u0131n en a\u00e7\u0131k g\u00f6stergelerinden biridir.<\/strong> E\u011fer CK d\u00fczeyleri Duchenne kas distrofisinin te\u015fhisinde ve takibinde \u00f6nemliyse, Elevidys sonras\u0131nda da \u00f6nemini koruyacakt\u0131r. CK e\u011filimlerine ili\u015fkin \u015feffafl\u0131k bir se\u00e7enek de\u011fil, bir zorunluluk olarak de\u011ferlendirilmelidir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DMDWarrior olarak, Duchenne kas distrofisi olan bir\u00e7ok ailenin s\u0131kl\u0131kla sordu\u011fu klinik sonu\u00e7lar, biyomarkerlar, uzun vadeli beklentiler ve gelecekteki tedavi hususlar\u0131 gibi konularla ilgili olarak Sarepta&#039;ya bir dizi soru y\u00f6nelttik.<\/strong> Bize yan\u0131t verilece\u011fi bilgisi verilmi\u015fti, ancak bu makalenin yay\u0131nland\u0131\u011f\u0131 tarih itibariyle bu sorulara ayr\u0131nt\u0131l\u0131 yan\u0131tlar almad\u0131k. Sarepta herhangi bir zamanda yan\u0131t vermeyi se\u00e7erse, hastalar\u0131n, ailelerin ve sa\u011fl\u0131k profesyonellerinin bilgileri do\u011frudan inceleyebilmeleri ve kendi sonu\u00e7lar\u0131n\u0131 \u00e7\u0131karabilmeleri i\u00e7in yan\u0131tlar\u0131n\u0131 eksiksiz olarak yay\u0131nlamaya haz\u0131r\u0131z.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Few Duchenne muscular dystrophy (DMD) treatments have generated as much excitement, controversy, and debate as Elevidys (delandistrogene moxeparvovec), the gene therapy developed by Sarepta Therapeutics. For many families, Elevidys represents hope. It is the first approved gene therapy designed to address the underlying genetic cause of Duchenne muscular dystrophy by delivering a micro-dystrophin gene to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8120,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282],"tags":[33,743,179,742,821],"class_list":["post-8116","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-elevidys","tag-elevidys-cost","tag-elevidys-gene-therapy","tag-elevidys-price","tag-sarepta-stock"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8116"}],"version-history":[{"count":9,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8116\/revisions"}],"predecessor-version":[{"id":8126,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8116\/revisions\/8126"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8120"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}